ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc.

Bayer AG ($BAYRY), Oric Pharmaceuticals Inc ($ORIC) announced an update on their ongoing clinical study. Himalayas-1 pushes Bayer AG (BAYRY) and Or...

Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial

Orica Limited ( ($AU:ORI) ) has shared an update. Orica Limited, a leading supplier of explosives and blasting systems to the mining and infrastruc...

Orica Names Catherine Brenner to Board, Reports No Initial Shareholding

The latest announcement is out from Orica Limited ( ($AU:ORI) ). Orica Limited has strengthened its board with the appointment of Catherine Brenner...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORIC	$12.86	+0.94%	991.45K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORIC	$12.86	+0.9%	991.45K
3
4
5
6

ORIC

Get ORIC Pharmaceuticals, Inc. Data in Excel

Get ORIC Pharmaceuticals, Inc. Data in Excel